Stock DNA
Pharmaceuticals & Biotechnology
SEK 213 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.34
955.09%
-28.86
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.75%
0%
-13.75%
6 Months
-29.7%
0%
-29.7%
1 Year
-5.31%
0%
-5.31%
2 Years
-10.12%
0%
-10.12%
3 Years
-76.36%
0%
-76.36%
4 Years
-87.21%
0%
-87.21%
5 Years
-92.16%
0%
-92.16%
Enorama Pharma AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.44%
EBIT Growth (5y)
-200.79%
EBIT to Interest (avg)
-17.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.76
Sales to Capital Employed (avg)
0.80
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-30.38
EV to EBIT
-3.51
EV to EBITDA
-5.03
EV to Capital Employed
-22.38
EV to Sales
19.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.70
0.40
75.00%
Operating Profit (PBDIT) excl Other Income
-14.80
-16.50
10.30%
Interest
3.40
5.80
-41.38%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-18.70
-22.50
16.89%
Operating Profit Margin (Excl OI)
-20,353.30%
-37,042.30%
1,668.90%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 75.00% vs -84.62% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 16.89% vs -2.27% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
15.80
1.40
1,028.57%
Operating Profit (PBDIT) excl Other Income
-30.30
-41.20
26.46%
Interest
0.40
0.90
-55.56%
Exceptional Items
-17.10
0.00
Consolidate Net Profit
-43.80
-44.60
1.79%
Operating Profit Margin (Excl OI)
-1,949.50%
-30,808.50%
2,885.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1,028.57% vs -79.41% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 1.79% vs -6.19% in Dec 2023
About Enorama Pharma AB 
Enorama Pharma AB
Pharmaceuticals & Biotechnology
Enorama Pharma AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company is mainly focused on the development of medical chewing gum that contains drugs. The Company's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The Company distributes its products in Europe through pharmacy chains and grocery stores.
Company Coordinates 
Company Details
Sodergatan 3 , MALMO None : 211 34
Registrar Details






